Claudine Chollet

684 total citations
10 papers, 547 citations indexed

About

Claudine Chollet is a scholar working on Hematology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Claudine Chollet has authored 10 papers receiving a total of 547 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Hematology, 8 papers in Genetics and 6 papers in Pathology and Forensic Medicine. Recurrent topics in Claudine Chollet's work include Chronic Myeloid Leukemia Treatments (10 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Lymphoma Diagnosis and Treatment (6 papers). Claudine Chollet is often cited by papers focused on Chronic Myeloid Leukemia Treatments (10 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Lymphoma Diagnosis and Treatment (6 papers). Claudine Chollet collaborates with scholars based in France, United Kingdom and India. Claudine Chollet's co-authors include François‐Xavier Mahon, Valérie Lagarde, Junia V. Melo, Josy Reiffers, John M. Goldman, Françis Belloc, François Moreau‐Gaudry, Vincent Praloran, Josy Reiffers and Gérald Marit and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and British Journal of Haematology.

In The Last Decade

Claudine Chollet

10 papers receiving 535 citations

Peers

Claudine Chollet
Laura N Eadie Australia
J. Chabrol France
Lisa Hopcroft United Kingdom
Andrew Kuykendall United States
Monique Ben‐Am Switzerland
Fabio P S Santos United States
Laura N Eadie Australia
Claudine Chollet
Citations per year, relative to Claudine Chollet Claudine Chollet (= 1×) peers Laura N Eadie

Countries citing papers authored by Claudine Chollet

Since Specialization
Citations

This map shows the geographic impact of Claudine Chollet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claudine Chollet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claudine Chollet more than expected).

Fields of papers citing papers by Claudine Chollet

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Claudine Chollet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claudine Chollet. The network helps show where Claudine Chollet may publish in the future.

Co-authorship network of co-authors of Claudine Chollet

This figure shows the co-authorship network connecting the top 25 collaborators of Claudine Chollet. A scholar is included among the top collaborators of Claudine Chollet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Claudine Chollet. Claudine Chollet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Dulucq, Stéphanie, Gabriel Étienne, Stéphane Morisset, et al.. (2019). Impact of second decline rate of BCR-ABL1 transcript on clinical outcome of chronic phase chronic myeloid leukemia patients on imatinib first-line. Annals of Hematology. 98(5). 1159–1168. 1 indexed citations
2.
Étienne, Gabriel, Stéphanie Dulucq, Françoise Huguet, et al.. (2019). Incidence and outcome of BCR‐ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors. Cancer Medicine. 8(11). 5173–5182. 15 indexed citations
4.
Bidet, Audrey, Claudine Chollet, Martine Gardembas, et al.. (2017). Molecular monitoring of patients with ETV6‐PDGFRB rearrangement: Implications for therapeutic adaptation. British Journal of Haematology. 182(1). 148–152. 4 indexed citations
5.
Dupouy, Maryse, Patricia Costaglioli, Claudine Chollet, et al.. (2011). α-Defensin 1-3 And α-Defensin 4 as Predictive Markers of Imatinib Resistance and Relapse in CML Patients. Disease Markers. 30(5). 221–227. 5 indexed citations
6.
Étienne, Gabriel, Maryse Dupouy, Patricia Costaglioli, et al.. (2011). α-defensin 1-3 and α-defensin 4 as predictive markers of imatinib resistance and relapse in CML patients.. SHILAP Revista de lepidopterología. 30(5). 221–7. 5 indexed citations
7.
Colombat, Marie, Claudine Chollet, Gérald Marit, et al.. (2006). Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment.. PubMed. 91(2). 162–8. 38 indexed citations
8.
Desplat, Vanessa, Valérie Lagarde, Françis Belloc, et al.. (2004). Rapid detection of phosphotyrosine proteins by flow cytometric analysis in Bcr‐Abl–positive cells. Cytometry Part A. 62A(1). 35–45. 14 indexed citations
9.
Mahon, François‐Xavier, Françis Belloc, Valérie Lagarde, et al.. (2003). MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood. 101(6). 2368–2373. 426 indexed citations
10.
Barthe, Christophe, Valérie Lagarde, Claudine Chollet, et al.. (2002). Mutation in the ATP‐binding site of BCR‐ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571. British Journal of Haematology. 119(1). 109–111. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026